GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Estrella Immunopharma
Estrella, an early-stage oncology biotech, is a highly speculative bet on its scientific platform. Its price is driven not by financial performance, but by news from preclinical and early clinical trials.
Share prices of companies in the market segment - Cancer blood
Estrella Immunopharma is a biopharmaceutical company developing T-cell-based cell therapies for the treatment of hematological and solid tumors. We've classified it in the "Blood Cancer" category. The chart below shows how investors view this cutting-edge, yet risky, biotech sector.
Broad Market Index - GURU.Markets
Estrella Immunopharma is a biopharmaceutical company developing T-cell-based cell therapies for the treatment of hematological and solid tumors. As a component of the GURU.Markets index, it represents the cutting-edge yet risky biotech sector. The chart below represents the entire market. See how this company's stock compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
ESLA - Daily change in the company's share price Estrella Immunopharma
For Estrella Immunopharma, Inc., an immuno-oncology company, daily price change is a measure of extreme volatility. It reflects the market's reaction to clinical trial data and is a critical parameter in risk assessment formulas.
Daily change in the price of a set of shares in a market segment - Cancer blood
Estrella Immunopharma, Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with ESLA's dynamics, which depend on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Estrella Immunopharma is a biotech company developing cell therapy for blood cancer. Its shares are a bet on a scientific breakthrough in medicine. Their high volatility, driven by research results, contributes to the dynamics of the entire innovative market sector.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Estrella Immunopharma
Estrella Immunopharma's year-over-year performance is a story of developing a new generation of cell therapy. Its market capitalization over the next 12 months depends entirely on progress in clinical trials of its CAR-T platforms. Success could offer new treatment options for patients with difficult-to-treat blood cancers.
Annual dynamics of market capitalization of the market segment - Cancer blood
As an early-stage biotech, Estrella is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about clinical trials of its immunotherapy. Its stock price will reflect investors' speculative belief in the potential of its developments.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Estrella is a clinical-stage biotech whose fate since its IPO has depended on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new cell therapy trials. The company's stock chart lives in a world of its own.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Estrella Immunopharma
Estrella Immunopharma is a biotech company focused on cell therapy. Its monthly performance is typical for the sector: it depends entirely on progress in its scientific developments and clinical programs. Partnerships and licensing announcements are key.
Monthly dynamics of market capitalization of the market segment - Cancer blood
Estrella Immunopharma is developing cell therapy for blood cancer, including using technology that could improve the safety and effectiveness of treatment. The chart below reflects the overall sentiment in the blood cancer treatment sector, where innovation plays a crucial role.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Estrella Immunopharma is a clinical-stage oncology company. Its shares represent a binary bet on the success or failure of its scientific developments. Their performance is completely disconnected from market cycles and is determined by news about the progress of clinical trials, which implies extreme volatility.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Estrella Immunopharma
Estrella Immunopharma is an early-stage biopharmaceutical company focused on cell therapy. Its weekly stock price reflects both high hopes and risks. Any news about preclinical trials, patents, or funding triggers extreme volatility, visible on the chart.
Weekly dynamics of market capitalization of the market segment - Cancer blood
Estrella Immunopharma is an early-stage biopharmaceutical company focused on cell therapy. Its weekly stock price reflects both high hopes and risks. Any news about preclinical trials, patents, or funding triggers extreme volatility, visible on the chart.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Shares of Estrella, a biotech company, live in a world of their own. Their performance is driven by news of scientific breakthroughs. A chart comparing the stock to the S&P 500 clearly demonstrates how the stock can rise or fall on company-specific events, completely ignoring the broader market.
Market capitalization of the company, segment and market as a whole
ESLA - Market capitalization of the company Estrella Immunopharma
Estrella Immunopharma's market capitalization is a biotech story focused on developing cell therapy (CAR-T) for the treatment of blood cancer. This early-stage company's stock price reflects investor confidence in its scientific platform. Its volatility is a direct market reaction to news about preclinical and early clinical trials.
ESLA - Share of the company's market capitalization Estrella Immunopharma within the market segment - Cancer blood
Estrella Immunopharma is a clinical-stage biopharmaceutical company developing cell therapy for blood cancer. Its market capitalization in its niche segment reflects investor expectations for its scientific platform. The chart below shows the valuation volatility, which depends on clinical trial progress.
Market capitalization of the market segment - Cancer blood
Estrella Immunopharma is a biopharmaceutical company developing cell therapy for the treatment of blood cancers. The chart below shows the overall market capitalization of the oncology sector. Its dynamics reflect the enormous investment and hopes associated with cell therapy, one of the most advanced approaches in the fight against cancer.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart shows a new strategy for fighting cancer. Estrella Immunopharma is developing a cell therapy targeting CD19, an important target in blood cancers. Its volatile line on the graph reflects the progress of clinical trials, visualizing the hope for more effective treatments for leukemia.
Book value capitalization of the company, segment and market as a whole
ESLA - Book value capitalization of the company Estrella Immunopharma
Estrella Immunopharma's book value is its scientific capital, consisting of the rights to cell therapy technologies (CAR-T) for the treatment of blood cancer, and its financial reserves. This is the foundation for clinical research. The chart shows how the biotech company manages its capital as it develops its innovative treatments.
ESLA - Share of the company's book capitalization Estrella Immunopharma within the market segment - Cancer blood
Estrella Immunopharma develops cell therapies for cancer treatment. Its strength lies in its unique scientific platforms and in-house CAR-T cell production capabilities. The chart shows the company's share of the complex and expensive physical infrastructure required to create these "living drugs."
Market segment balance sheet capitalization - Cancer blood
Immuno-oncology, as the BCap_Seg chart for biotech shows, is a knowledge-intensive field. Estrella Immunopharma operates in this environment, where capital is invested in clinical research and cell therapy development, not in giant factories. Its assets are intellectual property, not physical infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
Estrella Immunopharma's balance sheet represents capital invested in the development of cell-based cancer therapy. Its value reflects the financial basis for the creation of future production facilities that will create tangible "living drugs" to combat blood cancers.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Estrella Immunopharma
Estrella is an immunopharmaceutical company developing cell therapies for cancer. Its balance sheet is the money spent on research. Its market capitalization represents the hope for the success of its developments. The MvsBCap chart for such a company is a visualization of a roller coaster, where every ups and downs are driven by news from the lab or clinic, not financial reports.
Market to book capitalization ratio in a market segment - Cancer blood
Estrella Immunopharma is a biopharmaceutical company developing cell therapies for cancer treatment. Its value is entirely dependent on the success of its scientific developments. This chart shows how investors value the potential of its innovative platform, which is disproportionately higher than its tangible assets.
Market to book capitalization ratio for the market as a whole
Estrella Immunopharma develops cell therapy for blood cancer. This is a cutting-edge field of medicine, where a company's value is determined by its scientific developments and potential to save lives. Investors are buying not lab equipment, but the hope for a future breakthrough, which explains the huge premium to its book value.
Debts of the company, segment and market as a whole
ESLA - Company debts Estrella Immunopharma
Estrella, an early-stage immunopharmaceutical company, is dedicating its entire capital to preclinical and clinical research for the treatment of blood cancer. Until a commercial product is available, the company is entirely dependent on external funding. This chart reflects its financial strategy for survival and growth in the long and risky drug discovery process.
Market segment debts - Cancer blood
Estrella Immunopharma is a clinical-stage biopharmaceutical company developing cell therapies for the treatment of blood cancers. Funding expensive clinical trials is a key challenge for such companies. This chart illustrates how Estrella manages its capital to advance its innovative treatments through complex development stages.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Estrella Immunopharma
Estrella Immunopharma develops treatments for blood cancer, which requires significant investment in research. This chart shows how much the company relies on debt to finance its clinical trials. High debt is typical for biopharma, but it also carries the risk of bankruptcy if the research fails.
Market segment debt to market segment book capitalization - Cancer blood
Estrella Immunopharma is a biopharmaceutical company focused on developing cell therapies for the treatment of blood cancer. This chart reflects the debt burden in the oncology research sector. It allows one to assess how the company's financial strategy for funding lengthy and expensive clinical trials compares with industry standards.
Debt to book value of all companies in the market
Estrella Immunopharma is a biotech company focused on developing cell therapies for the treatment of blood cancer. This chart shows the overall financial situation. For a biopharma company in clinical trials, which requires significant investment, capital availability and investor sentiment are paramount.
P/E of the company, segment and market as a whole
P/E - Estrella Immunopharma
This chart of Estrella Immunopharma, a biopharmaceutical company targeting blood cancer, reflects investor faith in its scientific platform. The high stock price reflects the hope that its cell therapy will be successful in clinical trials and offer a new standard of care for patients.
P/E of the market segment - Cancer blood
This chart reflects the average P/E for the biotech sector where Estrella Immunopharma is developing. The industry's very high average valuation reflects hopes for scientific breakthroughs. The chart illustrates this general backdrop against which Estrella's potential for cell therapy in blood cancer is assessed.
P/E of the market as a whole
Estrella Immunopharma is a biopharmaceutical company developing cell therapy for blood cancer. Its technology aims to improve the efficacy and safety of treatment. The company's valuation is a bet on clinical success. This chart shows the overall interest in oncology and helps us understand whether Estrella's scientific approach stands out from other cell therapy companies.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Estrella Immunopharma
Estrella Immunopharma is a biopharmaceutical company developing cell-based therapies for blood cancer. Its valuation is almost entirely dependent on the success of clinical trials. This chart reflects analysts' expectations regarding the potential of its developments to become a new standard in cancer treatment.
%20P%2FE%20Estrella%20Immunopharma&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Estrella-Immunopharma&v=1772513743624 "Chart of the company's future (projected) P/E Estrella Immunopharma")
Future (projected) P/E of the market segment - Cancer blood
Estrella Immunopharma is a clinical-stage biopharmaceutical company developing cell therapies for the treatment of blood cancers. This chart plots its future profitability expectations against the broader biotech sector, allowing one to assess how highly the market values the potential of its research and development in the fight against hematological malignancies.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-blood&v=1772513743653 "Future (projected) P/E graph of the market segment - Cancer blood")
Future (projected) P/E of the market as a whole
Estrella Immunopharma is an early-stage biopharmaceutical company developing treatments for blood cancer. Its value depends almost entirely on future research success. This chart, which shows the market's risk appetite, is critically important. During periods of optimism, investors are more inclined to fund long-term, high-risk biotech projects like Estrella's.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513743670 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Estrella Immunopharma
Estrella Immunopharma is a biopharmaceutical company developing cell therapy for blood cancer. Its financial picture at this stage is primarily driven by clinical trial expenses. This chart illustrates the burn through investment capital during the development of innovative treatments, the success of which determines the company's future.
Profit of companies in the market segment - Cancer blood
Estrella Immunopharma is a clinical-stage biopharmaceutical company developing cell therapy (CAR-T) for the treatment of blood cancers. Its future depends on the success of clinical trials. This chart reflects the dynamics of the oncology sector, where breakthrough technologies can radically change treatment approaches and generate huge profits if approved.
Overall market profit
Estrella Immunopharma is developing cell therapy for cancer treatment. Like any early-stage biotech, its fate depends on the success of clinical trials and access to funding. This schedule, reflecting market sentiment, influences investor willingness to invest in long-term, high-risk scientific projects.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Estrella Immunopharma
Estrella Immunopharma is a biopharmaceutical company developing cell therapy for the treatment of blood cancer. Its future depends on the success of clinical trials and regulatory approval. This chart reflects analyst expectations, which are essentially an assessment of the likelihood of a scientific breakthrough and the future commercial potential of its developments.
%20profit%20of%20the%20company%20Estrella%20Immunopharma&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Estrella-Immunopharma&v=1772513743856 "Graph of future (projected) profit of the company Estrella Immunopharma")
Future (predicted) profit of companies in the market segment - Cancer blood
Estrella Immunopharma is a biotech company developing CAR-T cell therapy for the treatment of blood cancers. Its success depends on the results of clinical trials and the ability to commercialize innovative cancer treatments. This chart shows profitability forecasts for the biotech sector, reflecting the overall investment climate in this cutting-edge field of medicine.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-blood&v=1772513743880 "Graph of future (predicted) profits of companies in a market segment - Cancer blood")
Future (predicted) profit of the market as a whole
Estrella Immunopharma is a biopharmaceutical company developing cancer treatments. Its activities are funded by venture capital and are dependent on the overall biotech investment environment. This graph, reflecting market sentiment, indirectly impacts the availability of capital to fund the long-term and risky research Estrella is conducting.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513743901 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Estrella Immunopharma
Estrella Immunopharma is an early-stage biopharmaceutical company developing cancer therapies. For a company with virtually no revenue, this chart shows its estimated potential. Its market value is based solely on the company's scientific developments and future clinical successes.
P/S market segment - Cancer blood
Estrella Immunopharma is a clinical-stage biopharmaceutical company focused on developing immunotherapies for the treatment of blood cancers. This chart reflects the average revenue estimate in the biotech sector. It provides an idea of how highly investors value the potential future revenue from Estrella's innovative cell therapies.
P/S of the market as a whole
Estrella Immunopharma is a clinical-stage biopharmaceutical company developing cell therapies for the treatment of blood cancer. Their value lies in the potential of their scientific platform. This chart, reflecting the valuation of companies with existing revenue, serves as a benchmark for understanding the market's expectations for the future success of ESLA's drugs.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Estrella Immunopharma
Estrella Immunopharma is a biotechnology company developing CAR-T cell therapy for the treatment of blood cancer. This chart reflects investor expectations for the commercial potential of its developments. The valuation is entirely dependent on successful clinical trial results and future approval of its innovative cancer treatments.
%20P%2FS%20Estrella%20Immunopharma&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Estrella-Immunopharma&v=1772513744086 "The graph of the company's future (projected) P/S Estrella Immunopharma")
Future (projected) P/S of the market segment - Cancer blood
Estrella Immunopharma is a clinical-stage biopharmaceutical company developing innovative cell therapies (CAR-T) for the treatment of blood cancer. Its valuation is dependent on the success of clinical trials. This chart reflects market expectations for its future revenue if its developments are successful, compared to the biotech sector.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20blood&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-blood&v=1772513744112 "Future (projected) P/S market segment graph - Cancer blood")
Future (projected) P/S of the market as a whole
Estrella Immunopharma is a biotech company developing cell therapies for the treatment of blood cancer. Its value is based on the future potential of its developments. This chart, reflecting investors' overall risk appetite, is critical for Estrella. Market optimism allows such companies to more easily raise the capital needed to conduct expensive clinical trials.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513744150 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Estrella Immunopharma
Estrella Immunopharma is a biopharmaceutical company focused on developing cell therapy (CAR-T) for the treatment of blood cancers. This chart reflects its funding, which currently consists of grants, partnership payments, and funding, rather than commercial sales. It illustrates investments in cutting-edge immuno-oncology research.
Sales of companies in the market segment - Cancer blood
Estrella Immunopharma is a biotechnology company specializing in the development of innovative cancer immunotherapies, specifically CAR-T cell therapy. Its activities are segmented into various drug development programs. This chart depicts the financial flows associated with one of its key candidates, showing its progress in research.
Overall market sales
Estrella Immunopharma is a biopharmaceutical company developing cell therapies for cancer treatment. Its success is determined by scientific breakthroughs and clinical trial results, not by general economic trends. The company operates at the forefront of medicine, creating potential solutions for the most complex diseases, which provides enormous long-term value.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Estrella Immunopharma
Estrella Immunopharma is a clinical-stage biopharmaceutical company developing CAR-T cell therapy for the treatment of hematological malignancies. Its future sales forecast is a market assessment of the likelihood of success of its clinical programs and the potential commercial potential of its innovative approaches to treating blood cancers.
%20sales%20of%20the%20company%20Estrella%20Immunopharma&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Estrella-Immunopharma&v=1772513744395 "Schedule of future (projected) sales of the company Estrella Immunopharma")
Future (projected) sales of companies in the market segment - Cancer blood
Estrella Immunopharma is a biopharmaceutical company developing cell therapies for the treatment of blood cancers. This chart reflects aggregate expectations for the entire oncology sector. It helps understand the progress and commercial potential analysts are predicting for CAR-T and other advanced treatments, providing the backdrop for Estrella's developments.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-blood&v=1772513744415 "Schedule of future (projected) sales of companies in the market segment - Cancer blood")
Future (projected) sales of the market as a whole
Estrella Immunopharma, a biopharmaceutical company developing cell therapy for cancer, depends on the investment climate in the biotech sector. This chart of total sales forecasts reflects the overall economic climate, which influences investor risk appetite and funding for cutting-edge medical research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513744430 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Estrella Immunopharma
Estrella Immunopharma is a biopharmaceutical company developing cell therapy for the treatment of blood cancer. Currently in the clinical stage, it has no commercial revenue. This chart clearly illustrates the current financial reality: significant investments in science and research form the basis for potential future profitability.
Market segment marginality - Cancer blood
Estrella Immunopharma is a biopharmaceutical company developing cell therapies for the treatment of blood cancers. Operational efficiency in this cutting-edge field means optimizing costs for complex and expensive clinical trials. The chart provides insight into how the company manages its resources compared to its oncology competitors.
Market marginality as a whole
Estrella Immunopharma is a biotech company developing cell therapy for the treatment of blood cancer. Its value is based on the potential of its scientific developments. This chart shows the profitability of mature businesses, whereas ESLA's success depends on the results of clinical trials and the ability to offer patients new, effective treatments.
Employees in the company, segment and market as a whole
Number of employees in the company Estrella Immunopharma
Estrella Immunopharma is an early-stage biotech company developing cell therapies to fight cancer. This graph shows a small but growing team of scientists. For such a startup, expanding its staff is a key sign of progress in research and approaching clinical trials.
Share of the company's employees Estrella Immunopharma within the market segment - Cancer blood
Estrella Immunopharma is a biotechnology company developing cell therapies for the treatment of blood cancers. Its research is at the cutting edge of science and requires a team of highly specialized scientists. This chart shows its human resources contribution to this highly complex and vital area of oncology.
Number of employees in the market segment - Cancer blood
Estrella Immunopharma is a biopharmaceutical company developing cell therapies for the treatment of blood cancers. This chart reflects the workforce in this cutting-edge sector. The growing number of scientists and clinicians reflects the massive investment and rapid progress in CAR-T and other cell therapies, creating a competitive yet promising environment for Estrella.
Number of employees in the market as a whole
Estrella Immunopharma is a biopharmaceutical company developing cell therapy for the treatment of blood cancer. Its growth and hiring are entirely dependent on clinical trial success and investment, rather than the overall economic situation, as illustrated by the data in this chart.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Estrella Immunopharma (ESLA)
Estrella Immunopharma, Inc. develops cell therapies for the treatment of blood cancers. This chart demonstrates a very high market capitalization per employee. This is typical for research-stage biotech companies, where the entire market value is derived from the potential of their research, developed by a small research team.
%20of%20the%20company%20Estrella%20Immunopharma%20(ESLA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Estrella-Immunopharma-ESLA&v=1772513744872 "Chart of market capitalization per employee (in thousands of dollars) of the company Estrella Immunopharma (ESLA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer blood
Estrella Immunopharma is a biotech company focused on developing cell therapies for the treatment of blood cancer. In this field, a company's value is derived from its research and patents. This chart shows how investors assess the potential of their developments per scientist and employee, a key metric in biopharma.
%20by%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-blood&v=1772513744902 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer blood")
Market capitalization per employee (in thousands of dollars) for the overall market
Estrella Immunopharma is a clinical-stage biotech company developing cell therapies for the treatment of blood cancer. Its value is entirely dependent on the success of its research. The chart illustrates the high potential value the market attributes to the work of a small team of oncology scientists.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513744951 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Estrella Immunopharma (ESLA)
Estrella Immunopharma is a clinical-stage biopharmaceutical company specializing in cell therapy (CAR-T) for the treatment of blood cancers. At this stage, the company is likely unprofitable. This graph (likely negative) shows R&D intensity. It measures how much capital the company "burns" per scientist working on developing breakthrough cancer treatments.
%20Chart%20Estrella%20Immunopharma%20(ESLA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Estrella-Immunopharma-ESLA&v=1772513744979 "Company Profit Per Employee (in thousands of dollars) Chart Estrella Immunopharma (ESLA)")
Profit per employee (in thousands of dollars) in the market segment - Cancer blood
Estrella Immunopharma is a biopharmaceutical company developing cell therapy for blood cancer. In this knowledge-intensive industry, a small team of scientists can create a product of enormous value. This metric reflects the productivity of their R&D, allowing them to compare the effectiveness of their personnel investment with the biotech industry average.
%20in%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-blood&v=1772513744994 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer blood")
Profit per employee (in thousands of dollars) for the market as a whole
Estrella Immunopharma is a clinical-stage biotechnology company developing cell therapy (CAR-T) for the treatment of blood cancer. The company has no commercial revenue during the R&D phase. This negative metric reflects the cost of maintaining a highly qualified scientific team. It shows investors the extent of their investment in personnel working on the development of future breakthrough drugs.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513745033 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Estrella Immunopharma (ESLA)
Estrella Immunopharma is a clinical-stage biopharmaceutical company developing cell therapies for cancer. Currently, revenue per employee may be nonexistent. This graph is an indicator of future potential, demonstrating the commercial viability of its developments if approved.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Estrella-Immunopharma-ESLA&v=1772513745047 "Sales chart per company employee Estrella Immunopharma (ESLA)")
Sales per employee in the market segment - Cancer blood
Estrella Immunopharma is a clinical-stage biopharmaceutical company developing CAR-T therapy for cancer. In this R&D business, revenue (if any) comes from partnerships. This chart compares revenue per employee (scientist) to the industry average, reflecting how productive their scientific platform is in attracting capital.
Sales per employee for the market as a whole
Estrella Immunopharma is a clinical-stage biotech developing cell therapy (CAR-T) for the treatment of blood cancer. Like other companies at this stage (ACLX), they likely don't yet have commercial sales revenue. This graph would show $0 or revenue from rare partnerships, as all employees (scientists) are focused on R&D, not sales.
Short shares by company, segment and market as a whole
Shares shorted by company Estrella Immunopharma (ESLA)
Estrella Immunopharma is a biotech company developing CAR-T cell therapy for the treatment of blood cancer. This is a cutting-edge, but extremely competitive and expensive, field of medicine. This chart shows the number of investors who are skeptical of Estrella's scientific platform and its chances of beating out larger, wealthier competitors.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Estrella-Immunopharma-ESLA&v=1772513745132 "Short Shares Chart for the Company Estrella Immunopharma (ESLA)")
Shares shorted by market segment - Cancer blood
Estrella Immunopharma is a clinical-stage biopharmaceutical company developing CAR-T therapy for the treatment of blood cancer. This is a cutting-edge, but highly risky, segment of biotechnology. This chart illustrates the general market skepticism toward the cell therapy sector. Investors are shorting the industry, doubting the success of expensive clinical trials.
Shares shorted by the overall market
Estrella (ESLA) is a clinical-stage biotech company. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs, fearing ESLA won't be able to raise capital.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Estrella Immunopharma (ESLA)
Estrella Immunopharma is a biotech company specializing in CAR-T therapy for blood cancers. It's at the cutting edge of oncology. This chart measures the market's "temperature," showing when the stock is "overheated" (above 70) in anticipation of a breakthrough in trials or "oversold" (below 30) due to delays or setbacks.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Estrella-Immunopharma-ESLA&v=1772513745170 "RSI 14 indicator chart for the company's stock Estrella Immunopharma (ESLA)")
RSI 14 Market Segment - Cancer blood
Estrella Immunopharma is a biotech company developing cell therapy (CAR-T) for the treatment of blood cancers, specifically lymphoma and leukemia. This chart measures the collective excitement in the cell therapy sector. It helps determine whether the entire speculative segment is overheated by expectations.
RSI 14 for the overall market
For Estrella Immunopharma, a biotech in R&D, this chart is a lifeline showing capital availability. During moments of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the cash spigot is turned off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ESLA (Estrella Immunopharma)
Estrella Immunopharma is a biotech company developing cell therapy (CAR-T) for the treatment of blood cancers. This chart shows the average 12-month forecast of analysts. It represents their collective speculative bet on the success of this early-stage R&D platform's clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ESLA-Estrella-Immunopharma&v=1772513745284 "A chart showing analyst consensus forecasts for the expected stock price. ESLA (Estrella Immunopharma)")
The difference between the consensus estimate and the actual stock price ESLA (Estrella Immunopharma)
Estrella Immunopharma is a biotech company developing cell therapy (CAR-T) for the treatment of blood cancer. This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, reflecting their confidence in the company's early-stage R&D portfolio.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ESLA-Estrella-Immunopharma&v=1772513745323 "A chart showing the difference between the consensus forecast and the actual stock price. ESLA (Estrella Immunopharma)")
Analyst consensus forecast for stock prices by market segment - Cancer blood
Estrella is a biotech company working at the cutting edge of oncology—CAR-T cell therapy. Its R&D is aimed at "reprogramming" the immune system against blood cancers. This chart shows analysts' overall expectations for the blood cancer sector. It reflects whether experts believe CAR-T has a future or believe the market is overheated.
Analysts' consensus forecast for the overall market share price
Estrella Immunopharma is a biotech company developing cell therapy (CAR-T) for the treatment of blood cancers, specifically targeting CD19. This chart shows the overall risk appetite. For Estrella, working in one of the most advanced and expensive areas of medicine, overall market optimism is critical to attracting the capital needed to fund research.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Estrella Immunopharma
Estrella Immunopharma is a clinical-stage biotech company focused on developing cell therapies (CAR-T) for the treatment of blood cancers and solid tumors. This chart is a pure indicator of confidence in their R&D platform. It does not reflect revenue, but rather a speculative estimate of their scientific progress and clinical trial data.
AKIMA Market Segment Index - Cancer blood
Estrella Immunopharma (ESLA) is a biopharmaceutical company developing CAR-T cell therapy for the treatment of blood cancers, specifically targeting CD19. The chart shows the average index for the segment. It helps investors assess how Estrella competes in the crowded but important CAR-T sector relative to the average level of risk and expectations.
The AKIM Index for the overall market
Estrella Immunopharma is a biotech company developing T-cell therapies for the treatment of blood cancers and solid tumors. This chart, which reflects the market average, is an indicator of risk appetite. It shows the macro backdrop critical for funding this early-stage research platform.
